At a glance
- Originator Merz Pharma
- Class
- Mechanism of Action Glycine gated NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain; Stroke
Most Recent Events
- 16 Dec 2003 No development reported - Preclinical for Pain in Germany (unspecifed route)
- 27 Jun 2001 MRZ 2/571 is still in active development for chronic and visceral pain
- 27 Jun 2001 Discontinued-Preclinical for Stroke in Germany (unspecifed route)